SelectQuote Inc

SelectQuote Inc(SLQT)股票分析

$0.390

-0.080 (-20.61%)收盘时

Loading chart…
最高
0.496
开盘
0.484
成交量加权均价
0.42
成交量
2.03M
市值
463.49M
最低
0.360
成交额
844.31K
企业价值/息税折旧摊销前利润(TTM)
3.64

SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy.

AI 分析 of SelectQuote Inc (SLQT)

买入

SelectQuote Inc (SLQT) appears to be a good buy right now due to its recent price momentum and favorable valuation metrics. The current price is $0.402, which is significantly below its 52-week high of $2.17, indicating potential for recovery. The stock has shown a 5-day change of +22.90%, reflecting strong short-term performance. Additionally, the forward P/E ratio is 66.67, suggesting that while the stock is expensive based on earnings, it is trading at a low price-to-sales ratio of 0.0395, indicating it may be undervalued relative to its sales. However, the main risk is the negative earnings per share (EPS) estimate of -0.26 for the upcoming quarter, which could lead to further volatility.

估值指标

SelectQuote Inc(SLQT)当前预期市盈率为 66.67,5 年平均预期市盈率为 2.48。

预期市盈率

高估
5 年均值 P/E
2.48
当前P/E
66.67
高估
48.70
低估
-43.74

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
1.71
当前EV/EBITDA
3.64
高估
54.04
低估
-50.62

预期市销率

合理
5 年均值 P/S
0.29
当前P/S
0.06
高估
0.56
低估
0.03

Alphio AI 对 SLQT 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%SLQT

$2.27

情景价格

基

基准

基准 · 50%SLQT

$2.16

情景价格

悲

悲观

悲观 · 25%SLQT

$1.66

情景价格

持有 SLQT 的大户

A

Abrams Bison Investments, L.L.C.

+ 持有SLQT

+8.79%

3个月收益率

事件时间线

2026-11-04 (ET)

07:30:00

Sees FY27 Adjusted EBITDA of $90M-$115M

07:30:00

SelectQuote Reports Q1 Revenue of $280M

2026-08-25 (ET)

16:30:00

Major Averages Rise as Chip Stocks Benefit from Nvidia Earnings

12:30:00

Major Averages Slightly Higher, Chip Stocks Benefit from Nvidia Earnings

07:30:00

SelectQuote Q4 Revenue $321.7M, Below Consensus

资讯

SLQT 常见问题 —— 由 Alphio AI 解答

SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy. It operates in the Financials sector (INSURANCE AGENTS, BROKERS & SERVICE industry).

SelectQuote Inc (SLQT) appears to be a good buy right now due to its recent price momentum and favorable valuation metrics. The current price is $0.402, which is significantly below its 52-week high of $2.17, indicating potential for recovery. The stock has shown a 5-day change of +22.90%, reflecting strong short-term performance. Additionally, the forward P/E ratio is 66.67, suggesting that while the stock is expensive based on earnings, it is trading at a low price-to-sales ratio of 0.0395, indicating it may be undervalued relative to its sales. However, the main risk is the negative earnings per share (EPS) estimate of -0.26 for the upcoming quarter, which could lead to further volatility.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易